Follow Us :

PharmaGuru – Global Training for Pharmaceutical Careers

Blog

Avatar of Dr Pramod Kumar Pandey

By Dr Pramod Kumar Pandey - June 18, 2025

Dr. Pramod Kumar Pandey, PhD (Chemistry), is the Founder of PharmaGuru.co and a senior Analytical Research Expert with over 31 years of experience in the pharmaceutical industry. He specializes in analytical method development and validation, pharmaceutical research, quality control, quality assurance, and regulatory compliance, and has contributed to analytical innovation and quality excellence across leading Indian and global pharmaceutical companies. Contact: admin@pharmaguru.co

Reporting Results of Pharmaceutical Impurities: A Case Study

Reporting Results of Pharmaceutical Impurities: A Case Study

Reporting Results of Pharmaceutical Impurities
Image created in Bing

Reporting Results of Pharmaceutical Impurities

In addition to specification/limit, the detection limit (DL) of impurities, the quantification limit (QL) must also be considered when reporting pharmaceutical impurity results. Impurity data should be presented in a clear, structured, and accurate manner to ensure regulatory compliance and data integrity

Expert Tips

  • Don’t integrate the impurity peaks having a value less than DL (detection limit)
  • Integrate the impurity peaks having a value more than or equal to the DL (detection limit)
  • Impurities having a value less than or equal to QL (quantification) should not be included in the total impurities
  • Impurities having a value more than or equal to QL (quantification) should be included in the total impurities

Related:

Case Study: Certificate of Analysis (CoA)-Impurities Section

Product Name: [e.g., Paracetamol]
Batch Number: [e.g., ab123]
Date of Analysis: [e.g., 18-06-2025]
Test Method Reference: [e.g., In-house HPLC Method No. xyz]

Impurity NameLimit (% w/w)Impurities Result in ChromatogramReporting Result in COA
Impurity ANMT 0.10%0.07%0.07%
Impurity BNMT 0.15%0.02%<QL (QL = 0.03%)
Impurity CNMT 0.10%0.005%<DL (DL = 0.01%)
Any Unknown Unspecified ImpurityNMT 0.10%0.04%0.03%
Total ImpuritiesNMT 0.60%0.14%0.10%

Note:

  • DL = 0.01%
  • QL = 0.03%

Expert Tips:

  1. Results should differentiate known and unknown impurities.
  2. Use validated analytical methods.
  3. Ensure alignment with pharmacopoeial or internal specifications.
  4. If reporting to regulatory bodies, specify identification thresholds, reporting thresholds (RL), and qualification thresholds per ICH guidelines.

Related:

What is Pharmaceuticals Certificate Of Analysis (COA)

How do you ensure the accuracy and repeatability of the test results?

In pharmaceutical analysis, accuracy and repeatability are ensured by:

  • Using validated analytical methods following ICH or pharmacopeial guidelines.
  • Calibrating instruments regularly with certified reference standards.
  • Following Good Laboratory Practices (GLP) and Standard Operating Procedures (SOPs).
  • Running system suitability tests before sample analysis.
  • Performing replicate analyses and calculating %RSD (relative standard deviation) to assess repeatability.
  • Using quality control samples and known standards to verify accuracy.
  • Maintaining consistent environmental conditions and proper documentation throughout the process.

You may like:

  1. Relative Response Factor (RRF) in Pharmaceutical Analysis
  2. Control of Nitrosamine Impurities in Pharmaceuticals: Learn Easily in 7 Minutes
  3. What Is Photostability Testing Of New Drug Substances?

Further Reading

Accuracy and repeatability of the test results

Leave a Reply

error: Content is protected !!